Bharat Biotech COVID-19 vaccine claimed to have 80.6% efficacy
'Shot well tolerated in participants; adverse events balanced between vaccine and placebo arms of the trial'
Between hype and hope on Zika
Bharat Biotech's patent claim on vaccines to fight Zika is riddled with holes and rivals abroad are surging ahead
Viva Cuba for its vaccine revolution
Punching way above its weight, the tiny nation has developed five vaccines, and offers hope of vaccine equity across the world
Covaxin has not got emergency use approval from WHO since 6 months. Know the process here
The approval is stuck in the final fifth stage of the process when clinical data on safety, efficacy, quality and risk management plan are evaluated
Confronting head-on the vexed pricing of COVID -19 vaccines
It would cost anything between Rs 13,821 crore to Rs 1,10,568 crore to vaccinate the 20-44 age population
WHO finally gives emergency use nod for Covaxin
Those administered indigenous Indian vaccine against COVID-19 can now travel abroad unhindred
Bhopal Covaxin trial participants allege side-effects, irregularities
Bhopal-based rights group writes to PM and Union health minister, demanding that ongoing Covaxin trial be halted there
Moderna’s brazen patent grab on a COVID-19 jab
The US administration is finally putting its foot down on the appropriation of public research by drug firms
The world may soon get a vaccine against Chikungunya
A multi-country Phase II / III clinical trial of a vaccine led by the International Vaccine Institute in partnership with Bharat Biotech …
India readies for COVID-19 vaccination but vexed questions on the solution remain
The risks the country needs to prepare for, precautions it needs to take, the logistics required and, above all, the implications of it all for …
Bharat Biotech will begin clinical trials of Covaxin on 2-18 age group
The clinical trials will be conducted to evaluate Covaxin’s safety and efficacy on a population group left out of India’s current …
COVID-19 vaccines for all: India’s supply story deconstructed
Vaccination presents a way out of the COVID-19 mess India has landed in; but jabs are in short supply and there’s no clarity …
Vaccine production in South Africa: how an industry in its infancy can be developed
Only if investment is increased, sustained, and backed by political commitment, will the country have sufficient vaccine production capacity
COVID vaccines: How to make sense of reports on their effectiveness
Real-world trials come with some problems: The target of vaccination, what time it was rolled out and emerging variants
Delaying the second COVID-19 vaccine dose: A medical expert answers key questions
The uncertainty is around how long the protective effect of the first dose will last without a second shot
Bharat Biotech COVID-19 vaccine gets govt panel nod for emergency use: Experts express concern
Recommendation to drug controller for emergency approval to India’s indigenous product against COVID-19
COVID-19 Vaccine Watch: India tops number of COVID-19 vaccine doses arranged from manufacturers
However, in terms of the proportion of the population that can be vaccinated with these doses, Canada leads the charts
Where are the vaccines for UP’s May 1 COVID-19 vaccination drive
There is extreme shortage of COVID-19 vaccines in India’s largest state and its government is facing problems in procuring them
Centre signs deal with Serum Institute for 11 million COVID-19 vaccine doses: Sources
Talks on with Bharat Biotech; no official statement from government or manufacturers yet
COVID-19 vaccination begins in Bihar; 30,000 health workers to be inoculated today
The vaccination will be staggered over three phases with health and frontline workers and people of 50 to get the shot first
Why experts are not happy with India’s COVID-19 vaccine procurement, pricing policy
India only COVID-19 vaccine producer that has shifted burden onto citizens to pay for vaccines by opening private markets for them, experts say
Covaxin effective against UK Strain: What does this mean in absence of efficacy data?
Being a whole-virus vaccine doesn’t give Bharat Biotech product any advantage at this stage, say experts
Gujarat recipients gung-ho on COVID-19 vaccine
The state will vaccinate about 440,000 healthcare workers and 355,000 frontline workers in the first round
COVID-19 immunity: how long does it last?
In UK’s second wave, previously infected health workers were either completely protected from reinfection or were asymptomatic
The curious case of Covaxin royalties
ICMR’s contradictions and obfuscation on ownership of the vaccine’s intellectual property is not helping in the fight against COVID-…